Samil Pharmaceutical Co.,Ltd

KOSE:A000520 Rapport sur les actions

Capitalisation boursière : ₩324.2b

Samil PharmaceuticalLtd Résultats passés

Passé contrôle des critères 0/6

Samil PharmaceuticalLtd has been growing earnings at an average annual rate of 3%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 13.8% per year.

Informations clés

3.0%

Taux de croissance des bénéfices

3.7%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie11.3%
Taux de croissance des recettes13.8%
Rendement des fonds propres-0.7%
Marge nette-0.5%
Dernière mise à jour des bénéfices30 Jun 2024

Mises à jour récentes des performances passées

Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality

Mar 21
Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality

Recent updates

Optimistic Investors Push Samil Pharmaceutical Co.,Ltd (KRX:000520) Shares Up 29% But Growth Is Lacking

Sep 13
Optimistic Investors Push Samil Pharmaceutical Co.,Ltd (KRX:000520) Shares Up 29% But Growth Is Lacking

We Think Samil PharmaceuticalLtd (KRX:000520) Is Taking Some Risk With Its Debt

Sep 11
We Think Samil PharmaceuticalLtd (KRX:000520) Is Taking Some Risk With Its Debt

Investor Optimism Abounds Samil Pharmaceutical Co.,Ltd (KRX:000520) But Growth Is Lacking

Jul 29
Investor Optimism Abounds Samil Pharmaceutical Co.,Ltd (KRX:000520) But Growth Is Lacking

Does Samil PharmaceuticalLtd (KRX:000520) Have A Healthy Balance Sheet?

May 24
Does Samil PharmaceuticalLtd (KRX:000520) Have A Healthy Balance Sheet?

There's Reason For Concern Over Samil Pharmaceutical Co.,Ltd's (KRX:000520) Massive 29% Price Jump

Mar 30
There's Reason For Concern Over Samil Pharmaceutical Co.,Ltd's (KRX:000520) Massive 29% Price Jump

Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality

Mar 21
Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality

Here's Why Samil PharmaceuticalLtd (KRX:000520) Has A Meaningful Debt Burden

Apr 01
Here's Why Samil PharmaceuticalLtd (KRX:000520) Has A Meaningful Debt Burden

Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 141% Total Return On Their Investment

Mar 11
Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 141% Total Return On Their Investment

Are Dividend Investors Getting More Than They Bargained For With Samil Pharmaceutical Co.,Ltd's (KRX:000520) Dividend?

Feb 15
Are Dividend Investors Getting More Than They Bargained For With Samil Pharmaceutical Co.,Ltd's (KRX:000520) Dividend?

Should You Be Concerned About Samil Pharmaceutical Co.,Ltd's (KRX:000520) ROE?

Jan 20
Should You Be Concerned About Samil Pharmaceutical Co.,Ltd's (KRX:000520) ROE?

Why It Might Not Make Sense To Buy Samil Pharmaceutical Co.,Ltd (KRX:000520) For Its Upcoming Dividend

Dec 24
Why It Might Not Make Sense To Buy Samil Pharmaceutical Co.,Ltd (KRX:000520) For Its Upcoming Dividend

Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 221% Total Return On Their Investment

Dec 09
Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 221% Total Return On Their Investment

What Is The Ownership Structure Like For Samil Pharmaceutical Co.,Ltd (KRX:000520)?

Nov 18
What Is The Ownership Structure Like For Samil Pharmaceutical Co.,Ltd (KRX:000520)?

Ventilation des recettes et des dépenses

Comment Samil PharmaceuticalLtd gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

KOSE:A000520 Recettes, dépenses et bénéfices (KRW Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 24210,733-1,15564,5325,913
31 Mar 24204,905-78661,4615,870
31 Dec 23196,3461,66459,9625,601
30 Sep 23189,2932,60059,6385,249
30 Jun 23183,0601,33659,7524,342
31 Mar 23179,56634358,9073,553
31 Dec 22179,676-2858,5192,907
30 Sep 22170,510-4,98955,3642,359
30 Jun 22158,910-4,74051,2262,617
31 Mar 22147,877-5,61948,0472,948
31 Dec 21134,247-5,34743,7632,971
30 Sep 21129,974-2,76141,6343,007
30 Jun 21127,287-1,32740,7093,007
31 Mar 21122,79313238,9602,593
31 Dec 20122,9991,34137,9893,007
30 Sep 20123,11494036,5103,185
30 Jun 20122,30872937,0872,847
31 Mar 20123,1021,42937,4613,183
31 Dec 19121,10778637,4533,060
30 Sep 19114,364-1,25137,7923,060
30 Jun 19107,856-3,36837,0172,969
31 Mar 19102,805-6,46137,4982,619
31 Dec 1894,600-8,56337,3732,182
30 Sep 1896,882-5,16537,5802,026
30 Jun 1894,916-4,60536,9252,087
31 Mar 1892,286-2,79736,1681,987
31 Dec 1792,038-1,26736,7341,961
30 Sep 1790,658-1,43435,7921,938
30 Jun 1792,11889835,3571,605
31 Mar 1794,68594835,8821,447
31 Dec 1696,75888735,6671,254
30 Sep 1694,01030635,3091,047
30 Jun 1692,62514034,9091,136
31 Mar 1688,65655333,5031,121
31 Dec 1588,13658833,6881,119
30 Sep 1585,795-2,98635,2501,457
30 Jun 1585,439-6,17036,9031,831
31 Mar 1585,849-10,17939,2252,477
31 Dec 1485,461-11,19039,0112,790
30 Sep 1487,6831,14837,9982,841
30 Jun 1487,5453,60137,0612,126
31 Mar 1489,2077,19134,5622,182
31 Dec 1389,2297,93034,6312,046

Des revenus de qualité: A000520 is currently unprofitable.

Augmentation de la marge bénéficiaire: A000520 is currently unprofitable.


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: A000520 is unprofitable, but has reduced losses over the past 5 years at a rate of 3% per year.

Accélération de la croissance: Unable to compare A000520's earnings growth over the past year to its 5-year average as it is currently unprofitable

Bénéfices par rapport au secteur d'activité: A000520 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.9%).


Rendement des fonds propres

ROE élevé: A000520 has a negative Return on Equity (-0.66%), as it is currently unprofitable.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé